Pharma Pulse 9/10/24: Counterfeit Weight Loss Drugs & Potential Health Risks, AI Isn't Magic & more

Counterfeit Weight Loss Drugs & Potential Health Risks

In this part of their Pharmaceutical Executive video interview, UpScriptHealth's Peter Ax, Founder and CEO, and George Jones, Chief Operations Officer, discuss the issue of counterfeit weight loss drugs, and the potential health risks associated with them.

The Affordable Care Act: A Strong Card for Harris and the Democrats as Trump Says He Can Improve Upon It

Many provisions of the Affordable Care Act are popular and the healthcare reform law has brought the proportion of Americans without healthcare insurance down to an all-time low. As president, Donald Trump backed "repeal and replace" efforts.

A.I. Isn’t Magic, but Can It Be ‘Agentic’?

So-called agentic artificial intelligence doesn’t require a human to tell it what to do. At least, that’s the idea.

Battelle Awarded U.S. Department of Defense Contract to Develop an Improved Nerve Agent Countermeasure

Battelle and subcontractor CMC Pharmaceuticals announced their selection by the U.S. Department of Defense (DOD) to develop an improved nerve agent countermeasure to enhance the current standard of care for the warfighter and increase survivability. The contract, awarded through the Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense’s (JPEO-CBRND) Joint Project Manager for Chemical, Biological, Radiological, and Nuclear Medical (JPM CBRN Medical), funds the development of the medical countermeasure through FDA approval and is valued at over $53 million over 6.5 years.

Mac Winslow on LinkedIn

Storage and distribution is such a key factor in the cost of drugs, especially when temperature matters.

Have news you want us to share in Pharma Pulse? Reach out to Social Media Editor Miranda Schmalfuhs